[Featured Stock] Mediphron Surges on Approval of Non-Opioid Painkiller Phase 1 Clinical Trial

[Asia Economy Reporter Hyungsoo Park] Mediphron Divinity is showing strong performance. The news that it received approval for a Phase 1 clinical trial plan (IND) for a topical non-narcotic analgesic (1% MDR-652gel) from the Ministry of Food and Drug Safety (MFDS) appears to have influenced its stock price.

As of 9:29 AM on the 12th, Mediphron is trading at 4,525 KRW, up 8.38% from the previous day.

The topical non-narcotic analgesic '1% MDR-652gel' is a new drug substance developed through joint research with the U.S. National Institutes of Health (NIH). It is expected to suppress various neuropathic pains such as diabetic neuropathic pain, postherpetic neuralgia, postoperative pain, and cancer pain, which are not effectively relieved by conventional anti-inflammatory analgesics.

Youngdong Yoo, head of Mediphron's research institute, stated, "1% MDR-652gel has demonstrated strong analgesic efficacy and safety through non-clinical trials, and it can be applied to various neuropathic pains." He added, "This opens a path to simultaneously address chronic pain treatment and the misuse of narcotic analgesics."

This content was produced with the assistance of AI translation services.